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Upper limits of intraocular pressure
in glaucoma clinical trials
The parallel, randomized, double-masked, active-
controlled trial is generally thought to be the most rigorous
and unbiased design to adequately compare two glaucoma
medicines.1,2 Important to this design is the intraocular
pressure entry criteria. The lower limit of intraocular pres-
sure is usually set at least >21 mmHg to help assure the
study population has the appropriate diagnosis (ocular
hypertension or primary open-angle glaucoma).1,2
In contrast, an upper limit intraocular pressure may be
set in the entry criteria for safety reasons to help assure that
any subject randomized would experience a sufficient
decrease in intraocular pressure to control their glaucoma
throughout the clinical trial. However, little data are avail-
able that examines the impact of an upper limit on the
intraocular pressure results of clinical trials.
The purpose of this study was to review past parallel,
randomized, active-controlled, single- or double-masked
monotherapy glaucoma trials to determine the association
of the upper limit of intraocular pressure specified in the
entry criteria to baseline and active treatment intraocular
pressures.
Articles evaluated in this analysis were dated from
January 1995 to April 2011 and found on PubMed
(http://www.pubmed.gov) using the following search
terms: primary open-angle glaucoma, ocular hyper-
tension, intraocular pressure, diurnal, monotherapy,
baseline, reduction, beta-blockers (timolol, timolol gel-
forming solution, betaxolol, carteolol, levobunolol),
carbonic anhydrase inhibitors (dorzolamide, brinzola-
mide), alpha-agonists (brimonidine, brimonidine pre-
served with polyquaternium-1, brimonidine preserved
with chlorine dioxide, apraclonidine), prostaglandins
(latanoprost, travoprost, bimatoprost) and combination
therapy (brinzolamide/timolol, dorzolamide/timolol,
latanoprost/timolol, travoprost/timolol, brimonidine/
timolol, bimatoprost/timolol). Brand names of single and
fixed combination agents were also used as search terms.
Complete articles were retrieved and studies were
accepted into the database if they were randomized, pro-
spective, parallel, single- or double-masked, active-
controlled, monotherapy trials with at least 60 patients per
treatment arm and with 6 weeks of treatment. Only sub-
jects with ocular hypertension or primary open-angle glau-
coma were included. Studies with exfoliation and pigment
dispersion glaucoma patients were included if they each
comprised <10% of the total patient sample size. Studies
must have had both baseline and treated diurnal intraocu-
lar pressure measurements consisting of at least three time
points. Intraocular pressures must have been measured
with Goldmann applanation tonometry.
PRN Pharmaceutical Research Network, LLC analyzed
the data. The level to declare significance was .05 and all
analyses were two way. Mean intraocular pressure values
for the morning intraocular pressure and diurnal pressures
were analyzed between analyses methods by a one-way
analysis of variance test.3 Because of multiple comparisons,
we used a modified Bonferroni correction (α/2).
This study included 37 treatment arms from 22 studies,
of which 20 treatment arms were prostaglandin-related
compounds and 17 beta-blockers. Citations for the 22
studies can be found online (Supporting Information, Text
S1). The other classes of medicines did not have sufficient
treatment arms to provide a valuable comparison.
The results are shown in Table 1 and reveal, following
a modified Bonferroni correction, at baseline the upper
limit entry pressures of 34, 36 mm Hg or no upper limit
for prostaglandins; and upper limit entry pressures of
30, 34, 36 mmHg or no upper limit for beta-blockers
were statistically different for the morning and diurnal
intraocular pressures for both medicine classes (P ≤ 0.01).
Further, the pressures at the active treatment visit were
statistically different across groups for prostaglandins
for the morning (P = 0.004) and diurnal pressures
(P = 0.01).
In contrast, the active treatment visits for the morning
(P = 0.67) and diurnal intraocular pressures (P = 0.38)
were statistically similar for beta-blockers. Furthermore,
the intraocular pressure reduction from untreated baseline
for the morning and diurnal intraocular pressures for both
the prostaglandin and beta-blocker groups was not statis-
tically different across all three upper intraocular pressure
limits (P ≥ 0.06).
This study showed that the upper limit for the intraocu-
lar pressure as an entry criterion may affect both the base-
line and active treatment visit intraocular pressures. For
prostaglandins, a requirement of 34 or 36 mmHg or no
limit showed a statistical difference for the morning and
diurnal baseline intraocular pressures. Also a difference
was observed with beta-blockers between 30, 34 or
36 mmHg or no upper limit at both morning and diurnal
baseline intraocular pressures. This difference makes sense
as patients with higher untreated intraocular pressures at
baseline admitted to a clinical trial, should demonstrate a
resultant higher mean baseline intraocular pressure.
However, to our knowledge, this has not been previously
shown. Interestingly, studies with no upper limit of entry
criteria intraocular pressure failed to provide a higher
mean intraocular pressure than those with a limit of
36 mmHg for both prostaglandins and beta-blockers. The
reason for this is not known.
The reason for using an upper limit of intraocular pres-
sure in clinical trials usually is for safety reasons to prevent
enrolment of a patient with such high intraocular pressures
that, even with treatment, would risk glaucomatous pro-
gression during the study. An even lower upper limit entry
intraocular pressure might be required in studies when a
placebo is used as the control, or if only one eye is treated
leaving the contralateral eye untreated.
However, a higher upper limit entry intraocular pres-
sure may be desirable, in appropriate designs, to provide a
higher mean baseline intraocular pressure. It has been
shown that the higher the mean baseline intraocular
Competing/conflicts of interest: No stated conflict of interest.
Funding sources: No stated funding sources.
bs_bs_banner
84 Letters to the Editor
© 2014 Royal Australian and New Zealand College of Ophthalmologists
pressure, the greater the drop in intraocular pressure that
might occur with the active treatment.4 Theoretically, with
a greater drop in intraocular pressure, any differences
between two actives might be exaggerated, and the study
would more likely reach the 1.5 mmHg level, which is
typically used in clinical trial design to determine a statis-
tical difference in efficacy between treatment groups.
However, no study has demonstrated that higher baseline
intraocular pressures do indeed help differentiate the effi-
cacy between two treatments with more validity.
At the last active treatment visit, this study showed
among prostaglandin treatment arms that a statistical dif-
ference among upper limit entry intraocular pressures
continued to be observed for the morning and diurnal
intraocular pressure measurements. This was not the case
with beta-blockers, however. Further, the reductions from
baseline were not statistically significant for either prosta-
glandins or beta-blockers for either the morning or diurnal
intraocular pressure measurements among different upper
limit entry intraocular pressures. Therefore, this difference
between beta-blockers and prostaglandins in treatment
intraocular pressures was not confirmed by the lack of
difference in reduction of intraocular pressures. Accord-
ingly, it is difficult to determine currently if the differences
in treated intraocular pressures for prostaglandins based
on the level of untreated baseline intraocular pressures is
real or not. This study suggests that differences in the
upper limit for entry of intraocular pressure at baseline in
well-controlled clinical trials may influence the mean
intraocular pressure at baseline.
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Text S1. Articles reviewed.
Glaucoma drainage device exposure
in Asian eyes
The use of glaucoma drainage devices (GDD) has been
well established in the treatment of medically refractory
glaucoma.1 Tube exposure was reported as one of the main
late complications.2 It increases the risk of endophthal-
mitis3,4 and requires immediate attention. We aim to evalu-
ate the incidence of tube exposure in Asian eyes, and to
identify associations with it.
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Table 1. Prostaglandin and beta-blocker intraocular pressures (mmHg)













34 mmHg 3 25.0 ± 0.8 23.3 ± 0.5 17.9 ± 0.7 17.2 ± 0.5 7.1 ± 1.4 28 6.1 ± 0.9 26
36 mmHg 7 27.4 ± 1.0 26.2 ± 0.9 19.4 ± 0.7 18.6 ± 0.6 8.0 ± 0.8 29 7.6 ± 0.7 29
None 10 25.9 ± 0.7 24.6 ± 1.1 17.8 ± 1.0 17.3 ± 0.9 8.1 ± 1.0 31 7.2 ± 0.9 29
P values 0.0007 0.002 0.004 0.01 0.29 0.06
Beta-blockers
30 mmHg 2 24.4 ± 0.3 23.6 ± 0.1 19.1 ± 1.3 18.2 ± 0.7 5.3 ± 1.0 21 5.4 ± 0.6 23
34 mmHg 3 25.3 ± 0.5 23.5 ± 0.3 19.4 ± 0.3 18.6 ± 0.4 5.8 ± 0.4 23 4.9 ± 0.1 21
36 mmHg 6 27.1 ± 1.3 25.8 ± 1.3 20.1 ± 0.9 19.5 ± 0.9 7.0 ± 1.0 26 6.4 ± 1.0 24
None 6 26.5 ± 0.7 25.3 ± 0.7 19.6 ± 1.3 19.2 ± 1.2 6.8 ± 1.2 26 6.1 ± 1.2 24
P values 0.01 0.009 0.67 0.38 0.14 0.20
ATV, active treatment visit.
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